LPP-CT26–treated mice displayed the activation of CD4+ and CD8+ T cells rather quickly and transiently, i.e., within 6 to 24 hours, indicating rapid immune activation by LPP-formulated cancer vaccine in vivo (Fig. 2, F and G, and fig. This evidence concerns the gene DDX53 and cancer.